Home > Insider Trading > Filing (0000899243-21-023375)

Filing Details

Accession Number:: 0000899243-21-023375
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-11 20:07:46
Reporting Period:: 2021-06-09

Accepted Time:: 2021-06-11 20:07:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1655759	Arvinas Inc.	ARVN	Pharmaceutical Preparations (2834)	472566120

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1753537	G John Houston	C/O Arvinas, Inc. 5 Science Park, 395 Winchester Ave. New Haven CT 06511	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-09	700	$16.00	828,343	No	4	M	Direct
Common Stock	Disposition	2021-06-09	700	$80.15	827,643	No	4	S	Direct
Common Stock	Acquisiton	2021-06-10	43,886	$16.00	871,529	No	4	M	Direct
Common Stock	Disposition	2021-06-10	17,615	$80.52	853,914	No	4	S	Direct
Common Stock	Disposition	2021-06-10	11,784	$81.75	842,130	No	4	S	Direct
Common Stock	Disposition	2021-06-10	14,487	$82.46	827,643	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-06-09	700	$0.00	700	$16.00
Common Stock	Stock Option (right to buy)	Disposition	2021-06-10	43,886	$0.00	43,886	$16.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
86,620		2028-09-25	No	4	M	Direct
42,734		2028-09-25	No	4	M	Direct

Footnotes

The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0950 to $80.2150, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (3).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.9400, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.0800 to $82.0750, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (5).
The price reported in this Column 4 is a weighed average price. These shares were sold in multiple transactions at prices ranging from $82.0800 to $82.7600, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6).
This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.